Series C Round

Longbio Pharma is a biotech startup focused on developing innovative therapies for autoimmune and rare diseases. The company is advancing its leading pipeline product, a next-generation anti-IgE antibody (LP-003), which is currently in Phase III clinical trials and is preparing for Biologics License Application (BLA) submission in 2025. This funding round aims to support the late-stage clinical studies of LP-003, enhance team capabilities, and strengthen working capital. The investment will also facilitate the expansion of Longbio's research and development efforts, aiming to bring more innovative treatments to market for patients suffering from challenging health conditions. The company, founded in 2018 and headquartered in Shanghai, China, has a mission to address unmet medical needs in the field of immunology.